Controlled release and anti-proliferative effect of imatinib mesylate loaded sporopollenin (cas 12712-72-0) microcapsules extracted from pollens of Betula pendula

Add time:08/30/2019    Source:sciencedirect.com

sporopollenin (cas 12712-72-0) is a promising material for drug encapsulation due to its excellent properties; uniformity in size, non-toxicity, chemically and thermally resilient nature. Herein, morphologically intact sporopollenin microcapsules were extracted from Betula pendula pollens. Cancer therapeutic agent (imatinib mesylate) was loaded into the microcapsules. The encapsulation efficiency by passive loading technique was found to be 21.46%. Release behaviour of the drug from microcapsules was found to be biphasic, with an initial fast release followed by a slower rate of release. Imatinib mesylate release from the drug itself (control) was faster than from imatinib mesylate-loaded sporopollenin microcapsules. The release profiles for both free and entrapped drug samples were significantly slower and more controlled in PBS buffer (pH 7.4) than in HCl (pH 1.2) buffer. Cumulative drug release from IM-MES-loaded sporopollenin microcapsules was found to be 65% within 24 h for PBS, whereas release from the control was completed within 1 h. Also, a complete dissolution of control in HCl buffer was observed within first 30 min. MTT assay revealed that drug-loaded microcapsules were effective on WiDr human colon carcinoma cell line. B. pendula sporopollenin can be suggested as an effective carrier for oral delivery of imatinib mesylate.

We also recommend Trading Suppliers and Manufacturers of sporopollenin (cas 12712-72-0). Pls Click Website Link as below: cas 12712-72-0 suppliers

Prev:Immobilization and characterization of hemoglobin on modified sporopollenin (cas 12712-72-0) surfaces
Next:Evolution of the macromolecular structure of sporopollenin (cas 12712-72-0) during thermal degradation)